Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

NCT01670032 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

328

Enrollment

INDUSTRY

Sponsor class

Conditions

Impetigo

Interventions

DRUG: Experimental: CD07223 1.5 % Topical Gel BID
DRUG: Experimental: CD07223 1.5% Topical Gel TID
DRUG: Placebo Comparator: CD07223 vehicle gel BID
DRUG: Placebo Comparator: CD07223 vehicle gel TID

Sponsor

NovaBay Pharmaceuticals, Inc.